Mereo BioPharma (MREO) Net Margin (2023 - 2025)
Mereo BioPharma (MREO) posted quarterly Net Margin of 2923.2% for Q2 2025, down 220.91% quarter-over-quarter from 910.9% in Q4 2023.
Mereo BioPharma (MREO) Net Margin (2023 - 2025) Analysis & Trends
Mereo BioPharma (MREO) has reported Net Margin for 2 consecutive years, with 2923.2% the latest figure, recorded in Q2 2025.
- In Q2 2025, Net Margin changed N/A year-over-year to 2923.2%; the TTM figure through Dec 2025 stood at 10458.4% (changed N/A YoY), while the FY2025 annual figure was 10458.4%, changed N/A from the prior year.
- Net Margin fell to 2923.2% in Q2 2025 per MREO's latest filing, from 910.9% in the prior quarter.
- Across five years, Net Margin topped out at 910.9% in Q4 2023 and bottomed at 2923.2% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -539.31% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.90% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 12.74% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -3.12% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 12.09% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -16.51% |
| 10 | Mereo BioPharma | 47.15 Mn | 47.15 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -2,923.20% |
| Dec 31, 2023 | -910.90% |